VSEE HEALTH INC (VSEE)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$0.02+3.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Broken: Primary pillar broken — Operating income improves from negative $2.97M: metric not reported.
VSee is expanding through M&A deals, aiming to grow its business. The company is managing capital allocation actively despite challenges. Operating income was negative $2.97M in 2026-Q1 but improving this is a stated goal. The stock trades cheaply with a price to sales of 0.36, well below peers.
Operating income worsened from negative $2.25M in 2025-Q2 to negative $2.97M in 2026-Q1. The company is loss-making with negative free cash flow yield of -1.55%. Recent legal and capital allocation issues raise risks. The stock has fallen 56% from its high, reflecting deep market concerns.
The market prices in a weak outlook with implied growth of -39.5% over 3 years and a cheap valuation versus peers. Our fair value is about $0.51, close to the current price, reflecting skepticism on turnaround progress.
Breaks if: New significant financial obligations or equity dilution occur next 4 quarters
Focus on capital allocation including financing arrangements and managing financial obligations.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The company is currently loss-making and has volatile management, which adds to the uncertainty in its performance outlook.
The market seems to reflect a low level of confidence in VSEE, given its cheap valuation compared to peers. However, the current pricing does not fully account for the potential risks and challenges the company faces.
Management is focused on improving operating income and has shown some progress in reducing losses. However, the company remains at risk of missing earnings expectations due to its smaller size and erratic earnings history.
The future performance of VSEE will depend on broader sector trends, particularly the performance of larger healthcare companies. If these companies continue to perform well, it could provide a favorable backdrop for VSEE, but any negative shifts could impact its trajectory significantly.
The most important moves since the prior daily snapshot.
Confidence changed from 'low' to 'medium'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. The company issued convertible promissory notes totaling approximately $887,739 and entered into equity purchase agreements in 2026-Q2. These capital allocation actions demonstrate active management of financing and obligations, delivering on stated priorities.
“Entry into a Material Definitive Agreement. Labrys Convertible Promissory Note Financing on June 30, 2026.”
“Entry into a Material Definitive Agreement. Standby Equity Purchase Agreement on June 2, 2026.”
“Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.”
“Unregistered Sales of Equity Securities and related capital allocation events in June and July 2026.”
Breaks if: No meaningful M&A activity completed in next 4 quarters
Continue pursuing mergers and acquisitions as a strategic growth initiative.
Stated as a priority in 3 of last 3 quarters. The company entered into multiple material definitive agreements in 2026-Q2, including convertible promissory notes and settlement agreements. This shows active pursuit of M&A-related transactions, delivering on the stated growth focus.
“Entry into a Material Definitive Agreement. Labrys Convertible Promissory Note Financing on June 30, 2026.”
“Entry into a Material Definitive Agreement. Settlement Agreement and Mutual Release on July 21, 2026.”
“Entry into a Material Definitive Agreement. ClearThink Convertible Note Financing on June 22, 2026.”
Breaks if: Operating income remains worse than negative $2.0M over next 4 quarters
Over the next 1 to 3 years, VSEE's outlook is uncertain, hinging on sector performance and management execution. Not investment advice.